Oncotarget

Research Papers:

Combined HAT/EZH2 modulation leads to cancer-selective cell death

Francesca Petraglia, Abhishek A. Singh, Vincenzo Carafa, Angela Nebbioso, Mariarosaria Conte, Lucia Scisciola, Sergio Valente, Alfonso Baldi, Amit Mandoli, Valeria Belsito Petrizzi, Concetta Ingenito, Sandro De Falco, Valeria Cicatiello, Ivana Apicella, Eva M. Janssen-Megens, Bowon Kim, Guoqiang Yi, Colin Logie, Simon Heath, Menotti Ruvo, Albertus T.J. Wierenga, Paul Flicek, Marie Laure Yaspo, Veronique Della Valle, Olivier Bernard, Stefano Tomassi, Ettore Novellino, Alessandra Feoli, Gianluca Sbardella, Ivo Gut, Edo Vellenga, Hendrik G. Stunnenberg, Antonello Mai, Joost H.A. Martens _ and Lucia Altucci

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:25630-25646. https://doi.org/10.18632/oncotarget.25428

Metrics: PDF 899 views  |   HTML 1875 views  |   ?  


Abstract

Francesca Petraglia1,*, Abhishek A. Singh2,*, Vincenzo Carafa1,*, Angela Nebbioso1, Mariarosaria Conte3, Lucia Scisciola1, Sergio Valente4, Alfonso Baldi5, Amit Mandoli2, Valeria Belsito Petrizzi6, Concetta Ingenito6, Sandro De Falco7, Valeria Cicatiello7, Ivana Apicella7, Eva M. Janssen-Megens2, Bowon Kim2, Guoqiang Yi2, Colin Logie2, Simon Heath8, Menotti Ruvo9, Albertus T.J. Wierenga10, Paul Flicek11, Marie Laure Yaspo12, Veronique Della Valle13, Olivier Bernard13, Stefano Tomassi14, Ettore Novellino14, Alessandra Feoli15, Gianluca Sbardella15, Ivo Gut8, Edo Vellenga10, Hendrik G. Stunnenberg2, Antonello Mai4,16, Joost H.A. Martens2,1 and Lucia Altucci1

1Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Napoli 80138, Italy

2Department of Molecular Biology, Radboud University, HB Nijmegen 6500, The Netherlands

3IRCCS SDN, Napoli 80143, Italy

4Dipartimento di Chimica e Tecnologie del Farmaco ‘Sapienza’ Università, Roma 00185, Italy

5Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, Università della Campania ‘Luigi Vanvitelli’, Caserta 81100, Italy

6Ospedale Umberto I, Nocera Inferiore 84014, Italy

7Istituto di Genetica e Biofisica, Napoli 80131, Italy

8Centro Nacional de Análisis Genómico, Barcelona, Spain

9Istituto di Biostrutture e Bioimmagini, Napoli, Italy

10Department of Hematology, University of Groningen and University Medical Center Groningen, RB Groningen 9700, The Netherlands

11European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom

12Max Planck Institute for Molecular Genetics, Berlin, Germany

13Institute Gustave Roussy, Equipe labellisée Ligue Nationale contre le Cancer (LNCC), Universtité Paris-Saclay, INSERM U1170, Paris, France

14Dipartimento di Farmacia, Università di Napoli ‘Federico II’, Napoli 80131, Italy

15Dipartimento di Farmacia, Università degli Studi di Salerno, Fisciano I-84084, Italy

16Pasteur Institute, Cenci-Bolognetti Foundation, Sapienza University of Rome, Roma 00185, Italy

*These authors contributed equally to this work

Correspondence to:

Joost H.A. Martens, email: j.martens@ncmls.ru.nl

Lucia Altucci, email: lucia.altucci@unicampania.it

Keywords: cancer; epigenetics; apoptosis; acetylation; methylation

Received: March 15, 2018     Accepted: May 02, 2018     Published: May 22, 2018

ABSTRACT

Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce bona fide cancer-selective cell death in both solid and hematological cancers in vitro, ex vivo and in vivo xenograft models. Anticancer action was due to an epigenome modulation by H3K27me3, H3K27ac, H3K9/14ac decrease, and to caspase-dependent apoptosis induction. MC2884 triggered mitochondrial pathway apoptosis by up-regulation of cleaved-BID, and strong down-regulation of BCL2. Even aggressive models of cancer, such as p53–/– or TET2–/– cells, responded to MC2884, suggesting MC2884 therapeutic potential also for the therapy of TP53 or TET2-deficient human cancers. MC2884 induced massive apoptosis in ex vivo human primary leukemia blasts with poor prognosis in vivo, by targeting BCL2 expression. MC2884-treatment reduced acetylation of the BCL2 promoter at higher level than combined p300 and EZH2 inhibition. This suggests a key role for BCL-2 reduction in potentiating responsiveness, also in combination therapy with BCL2 inhibitors.

Finally, we identified both the mechanism of MC2884 action as well as a potential therapeutic scheme of its use. Altogether, this provides proof of concept for the use of epi-drugs coupled with epigenome analyses to ‘personalize’ precision medicine.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25428